object
present
studi
assess
mucos
cellular
humor
immun
respons
induc
two
differ
infecti
bronchiti
viru
ibv
vaccin
regim
efficaci
challeng
variant
ibv
onedayold
broiler
chick
vaccin
live
alon
group
combin
group
ii
two
group
vaccin
day
age
doa
one
group
kept
control
group
iii
signific
increas
lachrym
iga
level
observ
doa
peak
doa
vaccin
group
iga
level
group
ii
significantli
higher
group
doa
use
immunohistochemistri
examin
chang
number
cell
trachea
found
overal
pattern
cell
domin
compar
cell
two
vaccin
group
cell
significantli
higher
group
ii
group
doa
group
challeng
oculonas
virul
strain
doa
protect
assess
two
vaccin
group
gave
excel
ciliari
protect
although
group
ii
histopatholog
lesion
score
viral
rna
load
trachea
kidney
show
greater
level
protect
group
result
suggest
greater
protect
achiev
combin
vaccin
chick
follow
doa
citat
chhabra
r
forrest
lemier
awad
f
chantrey
j
ganapathi
k
mucos
cellular
humor
immun
respons
induc
differ
live
infecti
bronchiti
viru
vaccin
regim
protect
confer
infecti
bronchiti
viru
strain
prevent
infecti
bronchiti
ib
chicken
achiev
use
live
inactiv
vaccin
provid
protect
virul
field
ib
virus
ibv
event
exposur
despit
prevent
measur
outbreak
ib
frequent
occur
mani
poultri
produc
countri
probabl
due
emerg
new
variant
infecti
bronchiti
viru
success
protect
chicken
infect
essenti
identifi
preval
genotyp
region
determin
crossprotect
potenti
avail
vaccin
optim
strateg
vaccin
program
ib
first
describ
unit
state
identifi
unit
kingdom
thereaft
mani
ibv
variant
isol
europ
significantli
variant
call
emerg
later
ibv
qx
first
identifi
china
spread
europ
anoth
ibv
genotyp
genet
serolog
distinct
classic
ibv
also
report
china
middl
east
europ
contain
strain
effect
vaccin
program
need
howev
littl
known
cross
protect
induc
commerci
avail
vaccin
vaccin
regim
variant
effect
longlast
protect
ibv
infect
requir
activ
effector
memori
cellmedi
humor
immun
respons
hir
viru
number
studi
report
system
local
humor
immun
respons
ibv
vaccin
chicken
experiment
challeng
ibv
develop
cellmedi
immun
respons
cmi
correl
effect
viru
clearanc
reduct
clinic
sign
resolut
lesion
presenc
cytotox
lymphocyt
ctl
repres
good
correl
decreas
infect
correspond
reduct
clinic
sign
ctl
activ
major
histocompat
complex
restrict
cell
mediat
cytolysi
addit
shown
transfer
ctl
obtain
spleen
ibvinfect
chicken
protect
naiv
chick
subsequ
ibv
challeng
cours
experiment
viral
infect
kotani
et
al
show
clearanc
ibv
tracheal
mucosa
occur
earli
phase
infect
ctl
tracheal
mucosa
propos
involv
clearanc
date
inform
avail
tracheal
mucos
leukocyt
vaccin
live
ibv
vaccin
nevertheless
okino
et
al
quantifi
rel
express
ctl
gene
tracheal
sampl
vaccin
challeng
bird
upregul
gene
tracheal
mucosa
fulldosevaccin
bird
significantli
increas
h
postinfect
hpi
demonstr
develop
memori
cmi
howev
research
directli
measur
activ
cmi
cytotox
mechan
ctl
despit
report
kinet
relationship
local
system
hir
cmi
induc
differ
ibv
vaccin
regim
need
better
understood
protect
emerg
ibv
strain
thu
object
studi
measur
local
system
hir
cmi
induc
two
differ
ibv
vaccin
regim
administ
commerci
broiler
chick
estim
protect
achiev
recent
isol
virul
strain
obtain
broiler
chick
age
day
commerci
hatcheri
bird
allow
ad
libitum
access
feed
drink
water
procedur
undertaken
accord
unit
kingdom
legisl
use
anim
experi
permit
project
licens
ppl
approv
univers
liverpool
ethic
review
committe
challeng
viru
virul
isol
use
studi
kindli
provid
merial
anim
health
pcr
confirm
allanto
fluid
egg
use
propag
viru
free
newcastl
diseas
avian
influenza
infecti
bursal
diseas
infecti
laryngotrach
avian
metapneumovirus
ibv
also
free
bacteri
fungal
contamin
viru
titrat
chicken
tracheal
organ
cultur
toc
describ
express
median
ciliostat
dose
cd
per
millilit
vaccin
prepar
recommend
manufactur
merial
anim
health
limit
unit
kingdom
vaccin
prepar
thoroughli
mix
one
vial
live
ibv
bioral
h
vaccin
ml
steril
water
sw
combin
vaccin
one
vial
bioral
h
live
ibv
gallivac
vaccin
mix
togeth
ml
sw
immedi
prepar
vaccin
sw
kept
cold
box
chick
receiv
total
l
appropri
vaccin
ocularli
l
nasal
l
sw
quantifi
viru
titrat
live
ibv
vaccin
perform
use
specif
pathogen
free
spf
embryon
chicken
egg
ece
inocul
via
allanto
caviti
ece
examin
ibv
specif
lesion
curl
dwarf
embryo
day
postinocul
viral
titer
calcul
accord
reed
muench
express
egg
infect
dose
eid
ml
titer
vaccin
virus
use
log
eid
chick
log
eid
chick
strain
strain
respect
experiment
design
divid
broiler
chick
age
day
three
group
n
chicksgroup
tabl
chick
group
inocul
oculonas
l
live
vaccin
alon
group
ii
chick
inocul
oculonas
l
live
vaccin
simultan
chick
two
group
ii
inocul
live
vaccin
day
age
doa
group
iii
receiv
l
sw
oculonas
kept
control
sampl
birdsgroup
serum
tear
heparin
blood
collect
doa
sacrif
bird
tear
serum
sampl
store
blood
sampl
process
immedi
peripher
blood
mononuclear
lymphocyt
isol
five
chicken
group
per
interv
human
euthan
collect
approxim
cm
upper
trachea
oct
snapfrozen
liquid
nitrogen
immunohistochemistri
ihc
rest
trachea
use
tracheal
wash
doa
bird
group
challeng
via
ocularnas
rout
cd
bird
observ
daili
clinic
sign
day
postchalleng
dpc
bird
group
necropsi
tracheal
sampl
collect
portion
place
rnalat
qiagen
crawley
unit
kingdom
store
process
examin
viral
rna
load
remain
portion
examin
histopatholog
ciliostasi
test
kidney
group
also
taken
histopatholog
viral
rna
load
examin
sampl
collect
antibodi
detect
potenti
vaccin
induc
antibodi
product
assess
individu
use
sampl
serum
tear
tracheal
wash
tear
collect
use
sodium
chlorid
describ
immedi
centrifug
g
min
supernat
store
use
collect
tracheal
wash
trachea
clamp
two
arteri
forcep
end
wash
ml
phosphatebuff
salin
pb
use
syring
needl
collect
sampl
centrifug
g
min
supernat
store
use
elisa
detect
ibv
antibodi
serum
sampl
test
commerci
ibv
enzymelink
immunosorb
assay
elisa
kit
flockchek
idexx
laboratori
inc
westbrook
usa
immunoglobulin
iga
tear
tracheal
wash
assay
use
commerci
iga
chicken
elisa
kit
abcam
cambridg
unit
kingdom
two
assay
carri
accord
respect
manufactur
instruct
hemagglutin
inhibit
test
hemagglutin
inhibit
hi
test
hemagglutinin
ha
antigen
obtain
gd
anim
health
servic
devent
netherland
ha
antigen
prepar
laboratori
describ
earlier
hi
test
conduct
accord
standard
procedur
oie
use
ha
unit
antigen
per
well
hi
titer
read
reciproc
highest
dilut
show
complet
inhibit
hi
geometr
mean
titer
express
reciproc
log
cellular
immun
respons
analysi
lymphocyt
subset
ratio
peripher
blood
determin
percentag
tlymphocyt
subpopul
blood
collect
cephal
vein
heparin
tube
sigmaaldrich
co
st
loui
mo
usa
final
concentr
gml
blood
dilut
rpmi
medium
sigmaaldrich
co
prepar
blood
sampl
ml
layer
onto
ml
histopaqu
gradient
sigmaaldrich
co
centrifug
eppendorf
vial
g
centrifug
buffi
coat
form
mononuclear
cell
gentli
collect
wash
twice
rpmi
medium
adjust
cellsml
cell
resuspend
bovin
serum
albumin
bsa
sigmaaldrich
co
pb
block
solut
incub
room
temperatur
min
sampl
l
incub
antibodi
surfac
domain
mous
antichicken
isothiocyan
fitc
clone
mgml
southernbiotech
birmingham
al
usa
mous
antichicken
clone
mgml
southernbiotech
receptor
lymphocyt
antibodi
final
concentr
l
sampl
min
dark
stain
cell
detect
flow
cytometri
bd
accuri
bd
bioscienc
san
jose
ca
usa
count
lympho
cyte
unstain
cell
sampl
use
neg
control
adjust
threshold
ii
immunohistochem
detect
igabear
b
cell
tracheal
section
octembed
tracheal
sampl
cut
section
fix
icecold
aceton
min
air
dri
room
temperatur
store
stain
prior
stain
slide
remov
storag
air
dri
room
temperatur
min
endogen
peroxidas
inhibit
use
hydrogen
peroxid
pb
min
endogen
biotin
biotinbind
protein
tissu
section
block
block
serum
use
vectastain
elit
abc
kit
vector
laboratori
burlingam
ca
usa
follow
block
tissu
section
stain
overnight
dark
detect
iga
cell
use
mous
monoclon
antibodi
chicken
clone
mgml
clone
mgml
chicken
iga
clone
mgml
monoclon
antibodi
procur
southernbiotech
birmingham
al
usa
stain
procedur
perform
describ
earlier
sampl
averag
number
posit
microscop
field
calcul
cell
type
ciliari
protect
dpc
trachea
sampl
evalu
accord
standard
procedur
ciliari
movement
ciliari
protect
group
calcul
histopatholog
evalu
dpc
kidney
trachea
human
euthan
bird
collect
fix
formalin
tissu
embed
paraffin
wax
section
cut
thick
tissu
section
stain
hematoxylin
eosin
h
e
microscop
evalu
score
attribut
accord
histopatholog
sever
determin
recommend
describ
previous
real
time
rtqpcr
total
rna
extract
trachea
kidney
collect
challeng
bird
perform
immedi
use
rneasi
minikit
qiagen
crawley
unit
kingdom
accord
manufactur
instruct
quantif
viral
rna
done
quantit
realtim
revers
transcriptionpcr
rtqpcr
use
ibv
region
utr
genespecif
primer
probe
describ
previous
rtqpcr
perform
accord
manufactur
instruct
use
onestep
rtpcr
kit
qiagen
ng
total
rna
per
reaction
amplif
plot
record
analyz
threshold
cycl
c
determin
rotorgen
q
thermocycl
softwar
qiagen
c
valu
convert
logrel
equival
unit
reu
viral
rna
done
gener
standard
curv
five
dilut
extract
rna
infect
allanto
fluid
eid
describ
earlier
statist
analysi
comparison
mean
antiibv
antibodi
level
ratio
peripher
blood
immunohistochem
detect
igabear
b
cell
tracheal
section
perform
use
oneway
analysi
varianc
anova
follow
post
hoc
least
signific
differ
lsd
multiplecomparison
test
use
graphpad
prism
version
softwar
kruskalw
test
follow
dunn
test
use
statist
analysi
nonparametr
rtqpcr
histopatholog
evalu
data
differ
consid
signific
p
system
humor
immun
respons
elisa
day
vaccin
mean
matern
deriv
antiibv
antibodi
titer
subsequ
antibodi
level
three
group
declin
cutoff
point
doa
booster
vaccin
doa
signific
increas
antibodi
titer
doa
observ
group
ii
shown
fig
time
point
level
antibodi
significantli
differ
vaccin
group
p
doa
though
antibodi
titer
group
iii
alway
less
cutoff
valu
assay
ii
hi
test
level
serotyp
specif
antibodi
homolog
heterolog
antigen
evalu
hi
test
tabl
hi
antibodi
respons
antigen
use
show
signific
differ
p
group
doa
howev
lower
antibodi
respons
obtain
group
antigen
use
hi
test
heterolog
virus
use
vaccin
doa
mean
hi
antibodi
titer
significantli
higher
p
group
ii
group
iii
thereaft
doa
level
antibodi
group
ii
similar
significantli
higher
group
iii
p
doa
group
ii
show
signific
increas
hi
antibodi
respons
follow
revaccin
homolog
antigen
similar
increas
observ
group
sampl
day
thereaft
doa
hi
antibodi
titer
antigen
overal
significantli
higher
group
ii
log
group
log
group
iii
log
doa
titer
group
ii
higher
group
iii
p
doa
mean
hi
titer
significantli
higher
p
group
ii
group
mean
differ
log
iii
mucos
humor
immun
respons
group
ii
level
iga
tear
increas
significantli
p
compar
control
group
iii
doa
continu
rise
initi
peak
doa
vaccin
group
iga
valu
fell
second
vaccin
day
increas
slightli
doa
day
challeng
iga
level
group
ii
significantli
higher
p
group
doa
doa
end
observ
period
fig
level
iga
tracheal
wash
vaccin
group
detect
doa
peak
doa
declin
doa
signific
p
differ
level
iga
tracheal
wash
induc
two
vaccin
group
observ
time
fig
iga
level
tear
tracheal
wash
two
vaccin
group
significantli
higher
level
unvaccin
control
group
system
cellmedi
immun
respons
ratio
peripher
blood
flow
cytometri
result
show
doa
ratio
slightli
higher
two
vaccin
group
nonvaccin
group
although
signific
differ
p
ratio
vaccin
nonvaccin
group
observ
doa
fig
booster
vaccin
doa
ratio
doa
show
slight
increas
vaccin
group
significantli
higher
p
group
group
ii
iii
doa
ratio
significantli
higher
p
group
ii
group
iii
ii
mucos
cellmedi
immun
respons
trachea
kinet
igabear
b
lymphocyt
group
vaccin
day
age
one
group
group
iii
kept
control
b
signific
differ
group
n
per
group
homolog
well
heterolog
antigen
interv
repres
differ
letter
p
detect
iga
product
use
elisa
tear
tracheal
wash
b
chicken
n
per
group
vaccin
live
alon
group
combin
group
ii
day
two
group
vaccin
day
age
one
group
group
iii
kept
control
iga
antibodi
level
tear
tracheal
wash
control
chicken
group
iii
remain
detect
level
asterisk
indic
valu
two
vaccin
group
significantli
differ
p
time
point
error
bar
indic
standard
error
mean
trachea
studi
ihc
fig
number
lymphocyt
trachea
increas
significantli
p
doa
vaccin
group
compar
control
fig
number
cell
reach
peak
doa
group
doa
group
ii
gradual
decreas
doa
second
immun
cell
strongli
increas
number
doa
compar
nonvaccin
control
declin
differ
vaccin
group
ii
statist
signific
p
cell
subpopul
group
ii
start
increas
significantli
p
doa
reach
peak
doa
declin
fig
revaccin
doa
two
vaccin
group
show
strong
increas
number
cell
number
cell
significantli
higher
group
ii
group
doa
p
overal
dynam
cell
subpopul
two
vaccin
group
domin
cell
doa
igabear
b
cell
increas
vaccin
group
ii
peak
doa
show
signific
differ
compar
unvaccin
group
p
number
igabear
b
cell
significantli
higher
group
ii
group
doa
wherea
signific
p
differ
observ
two
vaccin
group
doa
fig
protect
challeng
clinic
sign
observ
either
vaccin
group
unvaccin
group
respiratori
sign
cough
sneez
head
shake
tracheal
rale
nasal
discharg
observ
dpc
highest
percentag
ciliari
protect
observ
group
ii
follow
group
unvaccin
challeng
group
group
iii
show
littl
protect
compar
vaccin
challeng
group
viral
rna
load
tracheal
sampl
collect
significantli
higher
p
log
reu
rna
unvaccin
challeng
group
iii
vaccin
group
ii
measur
realtim
rtqpcr
dpc
vaccin
group
ii
show
mean
log
reu
viral
rna
respect
signific
differ
group
fig
overal
viral
rna
kidney
sampl
group
low
compar
tracheal
sampl
viral
rna
load
kidney
group
iii
significantli
higher
p
group
ii
wherea
group
show
signific
differ
p
log
reu
viral
rna
either
group
ii
group
iii
histopatholog
lesion
trachea
kidney
induc
challeng
viru
group
dpc
mark
histopatholog
chang
occur
group
iii
nonvaccin
group
mean
score
show
signific
differ
group
ii
p
group
fig
mean
lesion
score
kidney
group
iii
significantli
higher
p
group
ii
wherea
group
show
signific
differ
p
mean
lesion
score
either
group
ii
group
iii
howev
overal
mean
lesion
score
kidney
low
compar
mean
tracheal
lesion
score
vaccin
regim
chosen
studi
group
base
research
demonstr
improv
protect
seen
reu
rna
trachea
kidney
measur
realtim
rtpcr
dpc
chicken
experiment
challeng
day
age
strain
ibv
n
per
group
chicken
previous
vaccin
live
alon
group
combin
group
ii
day
two
group
vaccin
day
age
one
group
group
iii
kept
control
receiv
steril
water
signific
differ
group
detect
kruskalw
test
follow
dunn
mean
test
indic
differ
letter
p
mean
histopatholog
score
lesion
trachea
kidney
sampl
dpc
chicken
experiment
challeng
day
age
strain
infecti
bronchiti
viru
n
per
group
chicken
previous
vaccin
live
alon
group
combin
group
ii
day
two
group
vaccin
day
age
one
group
group
iii
kept
control
inocul
steril
water
signific
differ
group
detect
kruskalw
test
follow
dunn
mean
test
indic
differ
letter
p
two
vaccin
use
differ
serotyp
research
emphas
vaccin
program
use
experi
may
protect
respiratori
tract
challeng
everi
new
ibv
serotyp
emerg
also
evid
despit
use
masstyp
vaccin
day
follow
vaccin
doa
group
studi
signific
number
new
ibv
still
emerg
field
condit
eg
qx
recent
therefor
order
optim
use
current
avail
vaccin
achiev
better
immun
assess
protect
newli
emerg
strain
vaccin
regim
group
ii
also
includ
work
day
age
chick
high
elisa
antiibv
antibodi
titer
group
declin
drop
cutoff
point
doa
group
receiv
vaccin
day
age
low
antibodi
level
may
result
partial
neutral
vaccin
viru
target
tissu
matern
antibodi
present
broiler
age
consequ
low
replic
vaccin
viru
poor
stimul
humor
respons
later
second
vaccin
doa
increas
antibodi
titer
observ
doa
day
challeng
group
ii
signific
differ
antibodi
level
vaccin
group
p
hi
antibodi
level
declin
doa
homolog
heterolog
viru
antigen
show
similar
pattern
declin
elisa
titer
interestingli
doa
signific
differ
vaccin
group
ii
term
level
antibodi
wherea
hi
titer
significantli
higher
group
ii
group
p
role
antibodi
control
ibv
infect
remain
controversi
worker
shown
circul
antibodi
titer
correl
protect
ibv
infect
howev
studi
demonstr
import
humor
immun
diseas
recoveri
viru
clearanc
studi
expect
higher
hi
titer
obtain
use
antigen
homolog
vaccin
strain
howev
chick
also
appear
protect
heterolog
challeng
may
due
presenc
local
immun
upper
respiratori
tract
induc
vaccin
reduc
replic
challeng
viru
role
iga
antibodi
import
mucos
immun
ibv
presenc
antibodi
tear
follow
ibv
antigen
inocul
report
previous
studi
gradual
increas
iga
level
observ
tear
two
vaccin
group
first
week
vaccin
result
agreement
previou
research
report
similar
kinet
lachrym
fluid
iga
product
vaccin
addit
second
vaccin
lachrym
iga
level
decreas
two
vaccin
group
though
level
group
ii
remain
significantli
higher
p
group
observ
may
indic
decreas
lachrym
iga
level
second
vaccin
like
due
partial
neutral
antiibv
iga
sharp
decreas
igaibv
vaccin
chick
also
observ
challeng
addit
signific
rise
specif
lachrym
iga
vaccin
chicken
detect
subsequ
challeng
arkibv
isol
explain
probabl
role
neutral
antibodi
lachrym
fluid
time
challeng
ibvspecif
iga
also
found
tracheal
wash
infect
ibv
strain
studi
pattern
iga
tracheal
wash
vaccin
group
ii
close
parallel
reach
peak
doa
thereaft
declin
doa
suggest
short
durat
local
humor
immun
trachea
although
conflict
report
rel
concentr
iga
avian
respiratori
tract
result
consist
hawk
et
al
show
iga
antibodi
tracheal
wash
day
vaccin
interestingli
two
vaccin
group
second
vaccin
caus
rise
tracheal
iga
level
similar
find
also
report
reveal
revaccin
homolog
ibv
h
strain
secondari
ibv
exposur
induc
secondari
secretori
antibodi
respons
tracheobronchi
wash
consist
notion
cmi
protect
ibv
next
sought
studi
level
system
local
cellular
immun
respons
cell
may
directli
produc
antivir
cytokin
increas
b
cell
activ
promot
prolifer
matur
function
activ
ctl
thu
play
critic
role
control
ibv
infect
ratio
cell
wide
shown
indic
gener
immun
system
statu
studi
ratio
show
signific
p
variat
among
group
doa
nevertheless
ratio
doa
found
significantli
higher
p
group
ii
group
iii
indic
second
vaccin
doa
group
ii
probabl
enhanc
cellular
immun
promot
differenti
prolifer
cell
peripher
blood
specif
data
regard
effect
differ
ibv
vaccin
ratio
peripher
blood
compar
present
find
howev
yohann
et
al
report
significantli
p
higher
ratio
ibvinfect
chick
control
addit
high
ratio
associ
increas
humor
incompet
chicken
low
ratio
reduc
respons
sheep
red
blood
cell
report
earlier
studi
significantli
p
higher
hi
titer
doa
group
ii
group
may
attribut
high
ratio
group
ii
time
point
howev
signific
relat
protect
remain
determin
result
ihc
tracheal
tissu
show
number
lymphocyt
start
increas
doa
two
vaccin
group
compar
control
doa
signific
differ
report
vaccin
group
cell
subpopul
two
vaccin
group
start
increas
significantli
p
doa
reach
peak
doa
declin
number
doa
suggest
infiltr
recruit
cell
occur
first
week
initi
ibv
vaccin
similar
find
present
studi
trachea
cell
recruit
respons
infect
maximum
day
postinfect
dpi
cell
recruit
dpi
report
raj
jone
work
also
show
overal
higher
infiltr
cell
cell
two
vaccin
group
observ
consist
previou
studi
cell
also
found
predomin
compar
cell
trachea
ibv
infect
moreov
current
studi
also
document
significantli
higher
number
cell
vaccin
chick
group
ii
group
doa
igabear
b
cell
vaccin
group
reach
peak
doa
howev
number
cell
significantli
higher
group
ii
group
doa
p
pattern
recruit
b
cell
later
either
class
cell
accord
earlier
studi
contend
local
immun
ibv
mediat
mainli
cell
studi
follow
challeng
ciliari
protect
higher
group
ii
vaccin
mix
vaccin
day
old
group
vaccin
day
old
alon
furthermor
result
rtqpcr
show
viral
rna
load
dpc
trachea
higher
group
group
ii
although
differ
statist
signific
p
agreement
score
histopatholog
trachea
show
damag
caus
higher
group
group
ii
show
signific
differ
mean
lesion
score
either
group
ii
group
iii
basi
tracheal
histopatholog
assess
chicken
group
ii
better
protect
group
better
protect
may
attribut
variou
factor
includ
discuss
although
antiibv
elisa
antibodi
titer
result
indic
signific
differ
two
vaccin
group
day
challeng
group
ii
show
higher
ciliari
protect
group
observ
consist
previou
studi
shown
circul
antibodi
level
minor
import
protect
respiratori
mucosa
ibv
challeng
result
appear
overal
higher
protect
may
due
significantli
higher
level
cell
tracheal
tissu
group
ii
group
day
challeng
previou
studi
shown
cell
import
contributor
viral
clearanc
respiratori
viru
infect
util
contactdepend
effector
function
gamma
interferon
tumor
necrosi
factor
alpha
therefor
may
specul
group
ii
higher
cell
reaction
group
may
contribut
faster
viral
clearanc
challeng
explain
differ
tracheal
protect
vaccin
group
possibl
explan
agre
studi
emphas
involv
local
cell
infect
chicken
respiratori
pathogen
newcastl
diseas
viru
mycoplasma
gallisepticum
addit
group
ii
higher
level
iga
lachrym
fluid
group
reduc
tracheal
histopatholog
damag
also
corrobor
hypothesi
tradit
role
iga
prevent
pathogen
entri
mucos
surfac
neutral
viru
infect
epitheli
cell
ibvspecif
iga
antibodi
lachrym
fluid
correl
resist
ibv
reinfect
result
agreement
recent
studi
okino
et
al
author
conclud
ibv
iga
antibodi
lachrym
secret
express
granzymea
gene
tracheal
tissu
vaccin
provid
reliabl
approach
monitor
immun
protect
statu
trachea
shown
examin
ciliostasi
histopatholog
viral
replic
studi
aim
stain
varieti
cellsurfac
marker
therebi
identifi
cell
popul
infiltr
trachea
provid
inform
role
cellmedi
immun
protect
given
differ
live
ibv
vaccin
regim
novel
ibv
challeng
result
rtqpcr
score
histopatholog
kidney
show
damag
caus
higher
group
group
ii
show
signific
differ
mean
lesion
score
either
group
ii
group
iii
specif
cytotox
lymphocyt
shown
import
system
clearanc
nephropathogen
ibv
reduct
kidney
lesion
plausibl
explan
higher
cell
respons
tracheal
tissu
portal
entri
challeng
viru
group
ii
group
may
prevent
challeng
viru
becom
virem
thu
fail
reach
kidney
provid
effici
prevent
kidney
infect
measur
viral
rna
load
histopatholog
lesion
score
renal
tissu
conclus
chick
vaccin
day
old
follow
doa
show
significantli
higher
respons
trachea
higher
lachrym
iga
level
vaccin
alon
term
ciliari
protect
though
two
vaccin
group
protect
combin
vaccin
day
old
chick
follow
doa
show
higher
ciliari
protect
lower
rna
load
trachea
kidney
wherein
histopatholog
lesion
reduc
studi
highlight
potenti
modul
chick
immun
respons
use
current
avail
live
vaccin
better
protect
variant
ibv
afford
document
provid
scientif
purpos
refer
brand
trademark
herein
inform
purpos
intend
commerci
purpos
dilut
right
respect
owner
brand
trademark
gallivac
regist
trademark
merial
trademark
properti
respect
owner
